RG7112

CAS No. 939981-39-2

RG7112( RG-7112 | RG 7112 )

Catalog No. M16726 CAS No. 939981-39-2

A potent and selective inhibitor of p53-MDM2 interaction; binds MDM2 with high affinity (Kd=11 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 53 In Stock
5MG 87 In Stock
10MG 155 In Stock
25MG 309 In Stock
50MG 470 In Stock
100MG 680 In Stock
500MG 1422 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    RG7112
  • Note
    Research use only, not for human use.
  • Brief Description
    A potent and selective inhibitor of p53-MDM2 interaction; binds MDM2 with high affinity (Kd=11 nM).
  • Description
    A potent and selective inhibitor of p53-MDM2 interaction; binds MDM2 with high affinity (Kd=11 nM); stabilizes p53 and activates the p53 pathway, leading to cell cycle arrest, apoptosis, and inhibition or regression of human tumor xenografts. orally bioactive.(In Vitro):RG7112 (0-5 μM) stabilizes wild-type p53 and induces p53 signaling in cancer cells. RG7112 effectively activates p53 functions in cancer cells.(In Vivo):RG7112 (25-200 mg/kg, single oral dose) activates p53 pathway and induces apoptosis in tumor cells in vivo.RG7112 (100 mg/kg, gavage once per day, 5 days/week for 3 weeks ) reduces tumor growth rate and increases survival in GBM models.
  • In Vitro
    Cell Proliferation Assay Cell Line:SJSA1 osteosarcoma cells.Concentration:0-5 μM.Incubation Time:0-60 hours.Result:Dose-dependently inhibited the growth and killed SJSA1 osteosarcoma cells expressing high levels of MDM2 protein due to MDM2 gene amplification.Cell Cycle Analysis Cell Line:HCT116 and SJSA1 cells.Concentration:0-5 μM.Incubation Time:48 hours.Result:Induced a dose-dependent cell cycle block in G1 and G2/M phase and depletion of the S phase compartment.
  • In Vivo
    Animal Model:Female Balb/c nude mice.Dosage:25-200 mg/kg.Administration:Orally, single dose.Result:At the highest dose level of RG7112 (200 mg/kg) only 1.2% (± 0.89 SD) of cells incorporated BrdU at 24 h post-dosing, vs. 14% (± 1.83 SD) of vehicle treated tumors.Animal Model:GBM cells were implanted into the brain of Athymic Nude mice (7 weeks old females, 10 animals/group).Dosage:100 mg/kg.Administration:Oral gavage, once per day, 5 days/week for 3 weeks.Result:Reduced tumor growth rate and increases survival in heterotopic and orthotopic animal models bearing MDM2-amplified GBM.
  • Synonyms
    RG-7112 | RG 7112
  • Pathway
    Apoptosis
  • Target
    MDM2-p53
  • Recptor
    Mdm2
  • Research Area
    Cancer
  • Indication
    ——

Chemical Information

  • CAS Number
    939981-39-2
  • Formula Weight
    727.7831
  • Molecular Formula
    C38H48Cl2N4O4S
  • Purity
    >98% (HPLC)
  • Solubility
    10 mM in DMSO
  • SMILES
    CCOC1=C(C=CC(=C1)C(C)(C)C)C2=NC(C(N2C(=O)N3CCN(CC3)CCCS(=O)(=O)C)(C)C4=CC=C(C=C4)Cl)(C)C5=CC=C(C=C5)Cl
  • Chemical Name
    Methanone, [(4S,5R)-4,5-bis(4-chlorophenyl)-2-[4-(1,1-dimethylethyl)-2-ethoxyphenyl]-4,5-dihydro-4,5-dimethyl-1H-imidazol-1-yl][4-[3-(methylsulfonyl)propyl]-1-piperazinyl]-

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Tovar C, et al. Cancer Res. 2013 Apr 15;73(8):2587-97. 2. Andreeff M, et al. Clin Cancer Res. 2016 Feb 15;22(4):868-76. 3. Vu B, et al. ACS Med Chem Lett. 2013 Apr 2;4(5):466-9.
molnova catalog
related products
  • RETRA

    RETRA is a small molecule mutant p53 reactivator that activates a set of p53-regulated genes and specifically suppresses mutant p53-bearing tumor cells in vitro and in mouse xenograft.

  • Serdemetan

    Serdemetan (JNJ 26854165) is a novel anticancer agent that inhibits the function of the E3 ligase HDM2.

  • DIMP53-1

    A novel small-molecule dual inhibitor of p53-MDM2/X interactions by potentially binding to p53.